Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

Journal of Ovarian Research

Aleksandra Damasiewicz-Bodzek³  Robert Partyka¹  Piotr Bodzek² 

[1] Department of Anesthesiology, Intensive Treatment and Emergency Medicine, Medical University of Silesia, Katowice, Poland;Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland;Department of Chemistry, Medical University of Silesia, Zabrze, Poland

关键词: Anti-Hsp60 and anti-Hsp65 in ovarian cancer;   

Others  :  801819
DOI  :  10.1186/1757-2215-7-30

 received in 2014-01-10, accepted in 2014-02-15,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to evaluate the concentrations of IgG antibodies against Hsp60 and Hsp65 in sera of patients with ovarian cancer at various stages of clinical progress and for different histopathological types of disease.

Methods

Serum samples from 149 patients with ovarian carcinoma and 80 healthy women were investigated. The concentrations of anti-Hsp60 and anti-Hsp65 antibodies were determined using the enzyme-linked immunosorbent assay technique.

Results

The mean concentrations of anti-Hsp60 and anti-Hsp65 antibodies in the patients with ovarian cancer did not differ significantly from the mean levels in healthy women. Analysis in relation to the clinical progression stage showed that the concentrations of these antibodies were higher when the neoplastic process was less advanced and at early stages significantly higher than in control group. Mean concentrations of both antibodies were not significantly different in relation to the histological type of the ovarian cancer. The use of chemotherapy as a primary anticancer treatment did not cause a significant change in the concentration of anti-Hsp60 antibodies, but the mean level of anti-Hsp65 after this treatment was significantly higher than in control group.

Conclusions

The immunological response to Hsp60/65 is increased in early clinical stages of ovarian cancer and the level of anti-hsp60/65 antibodies may be then a helpful diagnostic marker. Even antibodies against highly homologous Hsps may be cross-reactive only partially and differ by some functional properties.

【 授权许可】

   
2014 Bodzek et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Cohen M, Dromard M, Petignat P: Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol 2010, 119:164-166.
• [2]Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
• [3]Jolly C, Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000, 92:1564-1572.
• [4]Concannon CG, Gorman AM, Samali A: On the role of Hsp27 in regulating apoptosis. Apoptosis 2003, 8:61-70.
• [5]Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C: Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 2008, 12:743-761.
• [6]Habich C, Burkart V: Heat shock protein 60: regulatory role on innate immune cells. Cell Mol Life Sci 2007, 64:742-751.
• [7]Wu T, Tanguay RM: Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe? Cell Stress Chaperones 2006, 11:1-12.
• [8]Rowley MJ, Karopoulos C: Heat shock proteins autoantibodies. In Autoantibodies. Edited by Peter JB, Shoenfeld Y. Amsterdam, The Netherlands: Elsevier Science B.V; 1996:336-342.
• [9]Rabczyński M, Adamiec R, Olszewska-Roczniak J: Antibodies anti-HSP 60/65 - role in atherogenesis, arteriosclerotic plaque risk factor. Adv Clin Exp Med 2006, 15:933-939.
• [10]Pockley AG: Heat shock protein in health and disease: therapeutic targets or therapeutic agents? Expert Rev Mol Med 2001, 3:1-21.
• [11]Memarzadeh S, Berek JS: Advances in the management of epithelial ovarian cancer. J Reprod Med 2001, 46:621-630.
• [12]Hoskins WJ: Prospective on ovarian cancer: why prevent? J Cell Biochem 1995, 59(suppl.23):189-199.
• [13]Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009, 115:112-120.
• [14]Berek JS, Schultes BC, Nicodemus CF: Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003, 21(suppl.10):168s-174s.
• [15]Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than CA-125? Am J Obstet Gynecol 2008, 199:215-223.
• [16]Taylor DD, Gercel-Taylor C: Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (rewiev). Oncol Rep 1998, 5:1519-1524.
• [17]Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC: Use of combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008, 14:764-771.
• [18]Gercel-Taylor C, Bazzett LB, Taylor DD: Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 2001, 81:71-76.
• [19]Anderson KS, LaBaer J: The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
• [20]Nesterova M, Johnson N, Cheadle C, Cho-Chung YS: Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006, 1762:398-403.
• [21]Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J: Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005, 54:55-62.
• [22]Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N: Effects of blood collection conditions on ovarian cancer serum markers. PLoS One 2007, 2:e1281.
• [23]Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D: Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer petients. Int J Cancer 2004, 111:720-726.
• [24]Brichory F, Beer D, Le Naour F, Giordano T, Hanash S: Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001, 61:7908-7912.
• [25]Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang JM, Hsieh LL: Humoral response to p53 in human colorectal tumors: a prospective study of 1209 patients. Int J Cancer 2001, 94:859-863.
• [26]Vogl FD, Frey M, Kreienberg R, Runnebaum IB: Autoimmunity against p53 predicts invasive cancer with poor survival in patients with ovarian mass. Br J Cancer 2000, 83:1338-1343.
• [27]Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS: IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. Int J Cancer 2000, 87:824-828.
• [28]Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, Stevenson MA, Calderwood SK: Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 2005, 10:46-58.
• [29]Elpek GO, Karaveli S, Simsek T, Keles N, Aksoy NH: Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries: correlation with clinicopathologic factors and survival. APMIS 2003, 111:523-530.
• [30]Capello F, Rappa F, David S, Anzalone R, Zummo G: Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res 2003, 23:1325-1331.
• [31]Capello F: HSP60 and HSP10 as diagnostic and prognostic tools in the management of exocervical carcinoma. Gynecol Oncol 2003, 91:661.
• [32]Capello F, Bellafiore M, Palma A, David S, Marcianò V, Bartolotta T, Sciumè C, Modica G, Farina F, Zummo G, Bucchieri F: 60 kDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur J Histochem 2003, 47:105-110.
• [33]Lim R, Lappas M, Ahmed N, Permezel M, Quinn MA, Rice GE: 2D-PAGE of ovarian cancer: Analysis of soluble and insoluble fractions using medium-range immobilized pH gradients. Biochem Biophys Res Commun 2011, 406:408-413.
• [34]Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howel SB: Correlation of the survival of ovarian cancer petients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 1993, 11:891-898.
• [35]Schneider J, Jimenez E, Marenbach K, Romero H, Marx D, Meden H: Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients. Anticancer Res 1999, 19:2141-2146.
• [36]Trieb K, Gerth R, Windhager R, Grohs JG, Holzer G, Berger P, Kotz R: Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiology 2000, 201:368-376.
• [37]Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszyński T, Zamłyński J, Stołtny P, Skutil M: Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma. Int J Gynecol Cancer 2009, 19:1516-1520.
• [38]Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W, Pasqualini R: An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 2004, 23:8859-8867.
• [39]Abu-Hadid M, Wilkes JD, Elakawi Z, Pendyala L, Perez RP: Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines. Cancer Letters 1997, 119:63-70.
• [40]Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR: Expression of the heat shock proteins HSP27 in human ovarian cancer. Clin Cancer Res 1995, 1:1603-1609.
• [41]Mendez F, Sandigursky M, Kureekattil RP, Kenny MK, Franklin WA, Bases R: Specific stimulation of human apurinic/apyrimidinic endonuclease by heat shock protein 70. DNA Repair 2003, 2:259-271.
• [42]Nadin SB, Vargas-Roig LM, Cuello-Carrion FD, Ciocca DR: Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process. Cell Stress Chaperones 2003, 8:361-372.
• [43]Danieli MG, Candela M, Ricciatti AM, Reginelli R, Danieli G, Cohen IR, Gabrielli A: Antibodies to mycobacterial 65 kDa heat shock protein in systemic sclerosis (scleroderma). J Autoimmun 1992, 5:443-452.
• [44]de Graeff-Meeder ER, Rijkers GT, Voorhorst-Ogink MM, Kuis W, van der Zee R, van Eden W, Zegers BJ: Antibodies to human hsp60 in patients with juvenile chronic arthritis, diabetes mellitus, and cystic fibrosis. Pediatr Res 1993, 34:424-428.
• [45]Hoppichler F, Lechleitner M, Traweger C, Schett G, Dzien A, Sturm W, Xu Q: Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis 1996, 126:333-338.
• [46]Frostegård J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U: Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 1997, 29:40-44.
• [47]Wick G, Perschinka H, Millonig G: Atherosclerosis as an autoimmune disease: an update. Trends Immunol 2001, 22:665-669.
• [48]Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, Wick G: Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumonia: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999, 99:1560-1566.
• [49]Prohászka Z, Bánhegyi D, Ujhelyi E, Karádi I, Füst G: Antibodies against 60-kDa heat-shock proteins in human immunodeficiency virus infection. Ann NY Acad Sci 1998, 851:94-98.
• [50]Prohászka Z, Duba J, Horváth L, Császár A, Karádi I, Szebeni A, Singh M, Fekete B, Romics L, Füst G: Comparative study on antibodies to human and bacterial 60 kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur J Clin Invest 2001, 31:285-292.
• [51]Prohászka Z, Duba J, Lakos G, Kiss E, Varga L, Jánoskuti L, Császár A, Karádi I, Nagy K, Singh M, Romics L, Füst G: Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability. Int Immunol 1999, 11:1363-1370.
• [52]Handley HH, Yu J, Yu DT, Singh B, Gupta RS, Vaughan JH: Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli GroEL. Clin Exp Immunol 1996, 103:429-435.
• [53]Metzler B, Schett G, Kleindienst R, van der Zee R, Ottenhoff T, Hajeer A, Bernstein R, Xu Q, Wick G: Epitope specificity of anti-heat shock protein 65/60 serum antibodies in atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:536-541.
• [54]Birnie DH, Vickers LE, Hillis WS, Norrie J, Cobbe SM: Increased titres of anti-human heat shock protein 60 predict an adverse one year prognosis in patients with acute cardiac chest pain. Heart 2005, 91:1148-1153.
• [55]Pockley AG, Bulmer J, Hanks BM, Wright BH: Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones 1999, 4:29-35.